OmniSeq, Inc.

4 articles about OmniSeq, Inc.

• OmniSeq Receives New York State Approval for OmniSeq INSIGHT Genomic and Immune Profiling Test

  4/28/2021

  OmniSeq®, an innovator in next generation sequencing in oncology, announced the New York State Department of Health's Clinical Laboratory Evaluation Program has approved the OmniSeq INSIGHTSM test.

• OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify Patients Eligible for New, Targeted Therapy for Lung and Thyroid Cancer

  6/29/2020

  OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance® comprehensive genomic and immune profiling assay to detect the presence of rare alterations in the RET gene in the tumors of some patients with non-small cell lung cancer (NSCLC) and thyroid cancer

• OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP

  4/7/2020

  Leading molecular diagnostic company's new hire to support oncology product development strategy through leadership and medical guidance

• OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial

  7/31/2018

  OmniSeq, Inc.® announced it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial